Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 142397 in Healthy Subjects
NCT03995550Phase 1Withdrawn
- Sponsor
- LEO Pharma
- Start
- Jul 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AQ280 (14 cohorts), sponsored by LEO Pharma. Primary endpoints: Number of treatment-emergent adverse events per subject at Day 21, Having clinically significant abnormalities in systolic blood pressure at Day 21 and 4 more. Planned start Jul 2019; status: withdrawn.
02
Drugs
AQ280
Beyond the preview
Go deeper on NCT03995550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03995550.